The companies anticipate finalising the acquisition in the third quarter of 2026.
Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business ...
Stocktwits on MSN
EWTX stock hits record high – why Servier is shelling out $2.65B for Edgewise’s muscular dystrophy business
The acquisition includes Edgewise’s muscular dystrophy operations and its lead drug candidate, Sevasemten. ・Sevasemten is currently being evaluated in a pivotal trial for Becker muscular dystrophy and ...
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion ...
In addition to the upfront fee, Servier has committed up to $1.1 billion in regulatory and commercial milestones to acquire ...
The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say ...
Servier has signed the largest licensing deal in its history, paying $1.55 billion upfront for Edgewise Therapeutics' ...
Servier has announced an agreement to acquire the muscular dystrophy business of Nasdaq-listed biopharmaceutical company ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an ...
SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results